GW Pharma's Price Target Raised To $208 At Cantor

Cantor Fitzgerald has raised its price target on GW Pharmaceuticals PLC-ADR GWPH to $208/ADS from $182/ADS after additional positive Epidiolex results.

Epidiolex Significance

The recent data of Epidiolex presented at the American Epilepsy Society (AES) event showed “robustness and remarkable consistency” across two distinct forms of epilepsy, LGS and Dravet syndrome.

“The previously disclosed seizure reduction of about 40 percent in three distinct indications was corroborated by fresh data on responder analysis. About 40 percent of patients experience a >=50 percent seizure reduction,” analyst Elemer Piros wrote in a note.

Piros, who has a Buy rating on the shares, said GW dismissed the concern that the drug should be taken with clobazam for efficacy.

“The fact that non-clobazam treated patients received anti-seizure benefit from Epidiolex speaks volumes against the theory,” Piros highlighted.

The company expects to submit a single NDA covering both the LGS and Dravet indications by the end of first half of 2017, followed by an EU submission in the second half of 2017.

Additional Catalysts

Other upcoming catalysts for the stock include data readouts from the adult partial-onset epilepsy study with cannabinoid analogue CBDV in mid-2017 and results from a glioblastoma trial with mixed THC:CBD combination in the first quarter of next year.

At last check, ADRs of the Cambridge, U.K.-based GW Pharma had climbed 6.89 percent on the day to $120.06.